ArticleBMC pediatrics2026
Novel use of telitacicept in primary immune thrombocytopenia: a case report.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary immune thrombocytopenia (ITP) is generally a self-limiting disorder in children; however, a subset of cases becomes refractory to conventional treatments or progresses to chronic disease. Managing such refractory instances remains a significant clinical challenge. CASE PRESENTATION: We report the case of a 5-year-old child with refractory ITP that was not adequately controlled with standard therapies, including intravenous immunoglobulin, corticosteroids, and rituximab. Following disease recurrence and limited response to these interventions, the novel biologic agent telitacicept was administered. This intervention led to marked clinical improvement. The diagnostic evaluation, therapeutic course, and successful use of telitacicept are comprehensively detailed.
conclusionsThis case illustrates the potential benefit of telitacicept in the management of pediatric refractory ITP, particularly when conventional treatment options have been exhausted. Further studies are warranted to explore its efficacy and safety in similar challenging cases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.